# Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

> **NCT02856555** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 127 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Firsocostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02856555
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-08
- **Primary completion:** 2017-07-18
- **Final completion:** 2017-07-18
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2020-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856555, "Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02856555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*